Skip to Content

Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

This study on long-term follow-up in relapsed mantle cell lymphoma involved a combination of lenalidomide, rituximab, and ibrutinib. Conducted in the Nordic countries, it showed a median progression-free survival of 70.4 months, even in TP53 mutated cases. Elin Forsgren, Uppsala University, presents the study in this MEDtalk at EHA 2024.

Elin Forsgren

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top